Enveric Biosciences Q2 EPS $(0.76) Up From $(11.64) YoY
Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(0.76) per share. This is a 93.47 percent increase over losses of $(11.64) per share from the same period last year.
Stocks · News reference
Shares of psychedelic-related biotech companies are trading higher amid sympathy with AtaiBeckley after the company announced it will be acquired by Lilly in a deal worth up to $3.8 billion.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Enveric Biosciences, Inc. (ENVB)
Filed: 2026-08-14 AccNo: 0001493152-26-038385 Size: 260 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate
Enveric Biosciences reports new preclinical data supporting the non-hallucinogenic profile of its lead psychiatric drug candidate, EB-003.
Enveric Biosciences Announces New Preclinical Data That Further Supports The Non-Hallucinogenic Profile Of EB-003; GloSensor Assay Findings Align With Previously Reported BRET Data
Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay, which has been previously described in peer-reviewed scientific literature (Wang et al., 2022)1. The Promega
Guggenheim Maintains Buy on GH Research, Raises Price Target to $40
Guggenheim analyst Eddie Hickman maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $34 to $40.
Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $40
Cantor Fitzgerald analyst Charles Duncan maintains GH Research (NASDAQ:GHRS) with a Overweight and raises the price target from $35 to $40.